China’s Center for Drug Evaluation (CDE) website has indicated that a market filing by local firm ProteLight Pharma for its Category 1 product peceleganan (PL-5) has been accepted for review by the bureau. This development follows a licensing deal in January 2023, through which Chia Tai Tianqing obtained the exclusive commercialization rights to the drug in China.
Peceleganan: An Innovative Broad-Spectrum Anti-Infective Drug
Peceleganan is an innovative peptide broad-spectrum anti-infective drug with a unique sterilization mechanism, indicated for the treatment of secondary wound infections, including those resulting from diabetes foot, bedsore, and burns. This non-antibiotic anti-infective drug stands out for its strong bactericidal advantages against various drug-resistant bacteria, such as the superbug MRSA (methicillin-resistant Staphylococcus aureus) and NDM-1-containing multidrug-resistant Acinetobacter baumannii.
Implications for Drug-Resistant Infections
The acceptance of peceleganan for review by the CDE signifies a potential advancement in the treatment of drug-resistant infections in China. The drug’s ability to combat hard-to-treat bacteria could provide a new therapeutic option for patients suffering from secondary wound infections, offering a much-needed alternative to traditional antibiotics.-Fineline Info & Tech
